Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Director | September 26, 2022 | September 28, 2022 |
| ARYA Sciences Acquisition Corp VARYE · Entity 137308 | Director | July 12, 2021 | July 12, 2021 |
| ASP Isotopes Inc.ASPI · Entity 5371 | Director | June 29, 2026 | July 02, 2026 |
| Cerevel Therapeutics Holdings, Inc.ARYB · Entity 15182 | Director | June 04, 2020 | June 04, 2020 |
| Nautilus Biotechnology, Inc.ARYA · Entity 6679 | Director | August 06, 2020 | August 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date September 26, 2022 · Filed September 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,907 |
Reported balance
After 2022-09-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-09-26 · Grant · Acquired 13,400 · Balance 16,907 F1: All of the restricted stock will vest on September 26, 2023. F2: On July 1, 2022, the issuer effectuated a 1-for-25 reverse stock split. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the restricted stock will vest on September 26, 2023.
F2: On July 1, 2022, the issuer effectuated a 1-for-25 reverse stock split.
ARYA Sciences Acquisition Corp V
Report date July 12, 2021 · Filed July 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-07-12 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-257335) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-257335) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
ASP Isotopes Inc.
Report date June 29, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 672,247 |
Ending reported balance
After 2026-06-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-29 · Sale · Disposed 50,000 · Balance 722,247 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.21 to $6.31, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2026-06-30 · Sale · Disposed 50,000 · Balance 672,247 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.10 to $6.25, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.21 to $6.31, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.10 to $6.25, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Cerevel Therapeutics Holdings, Inc.
Report date June 04, 2020 · Filed June 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-06-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-238488) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-238488) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Nautilus Biotechnology, Inc.
Report date August 06, 2020 · Filed August 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-08-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-239986) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-239986) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARYA SCIENCES ACQUISITION CORP.
Report date July 01, 2020 · Filed July 07, 2020
Section 16 reporting ended · disclosed 2020-07-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-01 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities.
ARYA Sciences Acquisition Corp IV
Report date July 31, 2024 · Filed August 01, 2024
Section 16 reporting ended · disclosed 2024-08-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-31 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022153 · ownership.xml · derivative · entry 5 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-03-29 F2 · price: The options granted on May 20, 2020, May 21, 2019, March 29, 2018, December 14, 2017, December 13, 2016, February 11, 2016 and May 11, 2015 have each been modified to reflect a lower exercise price. F4 · derivative.exercise_date: The options vested 100% on September 29, 2018. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 19,827 | Not disclosed Strike: $7.42 | Not disclosed |
DisclosureSEC source: 0001493152-20-022153 · ownership.xml · derivative · entry 4 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,827 shares Expires 2029-05-21 F2 · price: The options granted on May 20, 2020, May 21, 2019, March 29, 2018, December 14, 2017, December 13, 2016, February 11, 2016 and May 11, 2015 have each been modified to reflect a lower exercise price. F3 · derivative.exercise_date: The options vested 100% on November 21, 2019. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 19,827 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022153 · ownership.xml · derivative · entry 3 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,827 Underlying: Common Stock · 19,827 shares Expires 2029-05-21 F2 · price: The options granted on May 20, 2020, May 21, 2019, March 29, 2018, December 14, 2017, December 13, 2016, February 11, 2016 and May 11, 2015 have each been modified to reflect a lower exercise price. F3 · derivative.exercise_date: The options vested 100% on November 21, 2019. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 21,518 | Not disclosed Strike: $3.20 | Not disclosed |
DisclosureSEC source: 0001493152-20-022153 · ownership.xml · derivative · entry 2 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,518 shares Expires 2030-05-20 F2 · price: The options granted on May 20, 2020, May 21, 2019, March 29, 2018, December 14, 2017, December 13, 2016, February 11, 2016 and May 11, 2015 have each been modified to reflect a lower exercise price. F1 · derivative.exercise_date: The options vest 100% on November 20, 2020. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 21,518 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022153 · ownership.xml · derivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,518 Underlying: Common Stock · 21,518 shares Expires 2030-05-20 F2 · price: The options granted on May 20, 2020, May 21, 2019, March 29, 2018, December 14, 2017, December 13, 2016, February 11, 2016 and May 11, 2015 have each been modified to reflect a lower exercise price. F1 · derivative.exercise_date: The options vest 100% on November 20, 2020. Read SEC document |
| November 02, 2020 Filed Nov 6, 2020 21:55 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 33,876 | $1.04 | $35,105.70 |
DisclosureSEC source: 0001493152-20-020709 · ownership.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 972,101 F1 · kind: The sales reported in this Form 4 were to cover tax obligations associated with vested restricted stock awards and were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.03 to $1.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 22:28 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 813,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-019385 · ownership.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,005,977 F1 · shares: The restricted stock will vest in 12 equal monthly installments beginning on October 31, 2020. Read SEC document |
| July 01, 2020 Filed Jul 7, 2020 01:57 UTC | ARYA SCIENCES ACQUISITION CORP. ARYA · Entity 147975 | Disposition to issuerClass B Ordinary Shares · Derivative | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950123-20-006744 · doc4.xml · derivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities. F1 · price: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities. F1 · derivative.exercise_date: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities. F1 · derivative.expiration_date: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:20 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 21,518 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001493152-20-009768 · ownership.xml · derivative · entry 2 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,518 Underlying: Common Stock · 21,518 shares Expires 2030-05-20 F2 · derivative.exercise_date: All of the stock options will vest on November 20, 2020. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:20 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 17,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-009768 · ownership.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,969 F1 · shares: All of the restricted stock will vest on November 20, 2020. Read SEC document |
| May 21, 2019 Filed May 23, 2019 22:25 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 19,827 | $0.00 Strike: $7.42 | $0.00 |
DisclosureSEC source: 0001144204-19-028027 · tv522353_4.xml · derivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,827 Underlying: Common stock · 19,827 shares Expires 2029-05-21 Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 22:04 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000318306-17-000004 · primary_doc.xml · derivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common stock · 30,000 shares Expires 2027-12-14 F1 · shares: 100% accelerated vesting on change of control. Read SEC document |
| December 13, 2016 Filed Dec 16, 2016 01:18 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0000318306-16-000054 · primary_doc.xml · derivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common stock · 50,000 shares Expires 2026-12-13 F1 · shares: 100% accelerated vesting on change of control. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 22:03 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000318306-16-000049 · primary_doc.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · shares: all 100,000 restricted common shares will vest on 1/1/18. Read SEC document |
| September 20, 2016 Filed Sep 28, 2016 12:34 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | PurchaseCommon stock | 5,000 | $5.48 | $27,400.00 |
DisclosureSEC source: 0000318306-16-000047 · primary_doc.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.